Antibody Fc Biology in Disease and Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 347
Special Issue Editor
2. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
3. Convergence Research Center for Dementia, Seoul National University Medical Research Center, Seoul, Republic of Korea
4. Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea
Interests: antibody engineering; FC domain engineering; FC receptors; onco-immunology; Alzheimer's disease
Special Issue Information
Dear Colleagues,
Antibodies are one of the most successful biomolecules as therapeutic agents, but we still do not know exactly what immune responses antibodies induce in adaptive and innate immunities. The antibody IgG, for example, binds to a several Fc receptors (six FcγRs, complement C1q, FcRL5, FcRn, TRIM21, and type II lectin receptors). The interaction between antigen-bound antibodies (immune complexes, ICs) and Fc receptors is capable of eliciting a variety of known and unknown immune responses. Thus, in order to maximize the therapeutic efficacy of antibodies, a better understanding of Fc receptors is essential. In addition, the engineered antibodies that have modulated the binding ability to Fc receptors have begun to be used and show enhanced efficacies.
Collectively, a better understanding of antibody functions in disease and therapy will provide the basis for developing new concepts of therapeutic antibodies.
This Research Topic will focus on (i) the diverse immunological functions of the Fc receptors and (ii) new engineered antibodies based on Fc biology.
Prof. Chang Han Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Fc receptors
- Complement
- Antibody
- Fc domain
- Engineered Fc domain
